HLA-G and neoplasm: Tumor-intrinsic determinants include loss of tumor immunogenicity (such as low tumor mutational burden, depletion of neoantigens, specific gene mutations, and the IPRES transcriptional signature), antigen presentation deficiency (related to alterations in the interferon-γ signaling pathway, loss of heterozygosity of human leukocyte antigen, and loss or mutation of β2-microglobulin and transporter associated with antigen processing), dysregulation of signaling pathways (including MAPK, PI3K, WNT, and IFN pathways), and loss or downregulation of PD-L1 expression [7].